Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity.
|
28657315 |
2017 |
Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
These results suggest that PEGylated NMU-8 has the therapeutic potential for treatment of obesity.
|
28400225 |
2017 |
Obesity
|
0.250 |
Biomarker
|
disease |
RGD |
After 1 month of the high-fat diet, however, the obesity-resistant rats showed significantly more NMU-induced physical activity compared to the obese DIO rats.
|
17706946 |
2007 |
Obesity
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
A total of 289 Czech children and adolescents with early-onset obesity and 84 Danish obese adults were analyzed for variants in NMU.
|
16984985 |
2006 |
Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
Screening of neuromedin U2 receptor (NMU2R) ligands may be very useful to treat obesity for the reason that centrally administered neuromedin U affects feeding behavior, energy expenditure, and pituitary.
|
16111886 |
2005 |
Obesity
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Studies of the neuromedin U-2 receptor gene in human obesity: evidence for the existence of two ancestral forms of the receptor.
|
15525579 |
2004 |
Albuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.
|
30220432 |
2018 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U: A Small Peptide in the Big World of Cancer.
|
31492042 |
2019 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The Cancer Genome Atlas data indicated that high YAP1 and NMU expression levels were associated with poor mean and overall survival.
|
31575084 |
2019 |
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
YAP1 overexpression induced NMU expression and transcription and promoted cell motility in vitro and tumor metastasis in vivo via upregulation of epithelial-mesenchymal transition (EMT), whereas specific inhibition of NMU in cells stably expressing YAP1 had the opposite effect in vitro and in vivo.
|
31575084 |
2019 |
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Neuromedin U (NMU), a neuropeptide isolated from porcine spinal cord and named because of its activity as a rat uterus smooth muscle contraction inducer, is emerging as a new player in the tumorigenesis and/or metastasis of many types of cancers.
|
31492042 |
2019 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results demonstrated that CPF increases tumor incidence and reduces latency of NMU-induced mammary tumors.
|
30290214 |
2019 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Analysis of different pancreatic cancer databases showed that Neuromedin U (NMU) expression was positively correlated with YAP1 expression in the tumor group.
|
31575084 |
2019 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
|
29107108 |
2018 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Overexpression of NmU also resulted in upregulation of epithelial-mesenchymal transition markers and increased IL-6 secretion which, together with aberrant metabolism, have all been associated with the cancer stem cell (CSC) phenotype.
|
28340506 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer.
|
28423716 |
2017 |
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The expression levels of Nmu in primary tumors with regional metastasis were higher, compared with those without metastasis.
|
27279246 |
2016 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Subsequently, the expression of Nmu was investigated using a tissue microassay to analyze the association between Nmu protein expression and Tumor Node Metastasis (TNM) status.
|
27279246 |
2016 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Thus, these results not only reveal the presence of previously uncharacterized heteromeric relationships among NMU receptors but also provide NMUR2S as a potential therapeutic target for the future treatment of NMU signaling-mediated cancers.
|
26317338 |
2015 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis.
|
24876102 |
2014 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis.
|
24876102 |
2014 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering.
|
19118941 |
2009 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.
|
16878152 |
2007 |
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
LHGDN |
Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2.
|
16878152 |
2007 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
|
16878152 |
2007 |